PEP-Therapy develops targeted peptide therapies for oncology, specifically focusing on PEP-010, which induces apoptosis in cancer cells and can be monitored through pharmacodynamic biomarkers. This approach addresses the challenge of treatment resistance in cancers such as ovarian adenocarcinoma, enhancing therapeutic efficacy both as a monotherapy and in combination with existing treatments like paclitaxel.
Funding
$1.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers develop resistance to existing treatments, requiring new therapeutic approaches to improve patient outcomes. Current oncology drugs may not effectively target the specific mechanisms driving cancer cell survival and proliferation. Monitoring the effects of cancer treatment can be challenging, hindering timely adjustments to therapy.
Solution
PEP-Therapy is developing targeted peptide therapies for oncology, with a focus on overcoming treatment resistance and improving therapeutic efficacy. Their lead product, PEP-010, is designed to induce apoptosis (programmed cell death) in cancer cells. PEP-010's mechanism of action can be monitored through pharmacodynamic biomarkers, allowing for real-time assessment of treatment response. PEP-Therapy's approach aims to enhance the effectiveness of cancer treatment, both as a standalone therapy and in combination with existing treatments like paclitaxel. The company's innovative peptides offer a targeted approach to address the challenges of cancer treatment and improve patient outcomes.
Target Audience
PEP-Therapy's primary target audience includes oncology researchers and clinicians seeking novel, targeted therapies to improve cancer treatment outcomes, as well as patients with cancers that have developed resistance to existing treatments.
Features
- PEP-010: A targeted peptide therapy designed to induce apoptosis in cancer cells.
- Pharmacodynamic biomarkers: Enable real-time monitoring of PEP-010's effects on cancer cells.
- Potential for use as a monotherapy or in combination with existing treatments like paclitaxel.
- Focus on overcoming treatment resistance in cancers such as ovarian adenocarcinoma.